8-K: ProMIS Neurosciences Executes 1-for-25 Reverse Stock Split

ProMIS Neurosciences Inc. announced a one-for-twenty-five reverse stock split to take effect on November 28, 2025, aimed at regaining compliance with Nasdaq's minimum bid price requirement.

Summary

• ProMIS Neurosciences Inc. has filed articles of amendment to effect a one-for-twenty-five (1:25) reverse stock split of its common shares.
• The reverse stock split will become effective at 12:01 a.m. Eastern Time on November 28, 2025.
• Trading on The Nasdaq Capital Market will commence on a split-adjusted basis at market open on November 28, 2025, under the existing symbol PMN.
• The primary purpose of the reverse stock split is to increase the market price of the common shares to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share.
• The company received a deficiency letter from Nasdaq on January 8, 2025, and was granted an extension until December 29, 2025, to cure the deficiency.
• The reverse stock split will reduce the number of outstanding common shares from approximately 53,811,110 to approximately 2,152,444.
• Proportional adjustments will be made to equity incentive plans, stock options, and warrants.
• No fractional shares will be issued; stockholders entitled to fractional shares will receive cash in lieu.
• The reverse stock split does not affect the number of authorized common shares or their par value.

Sentiment

Score: 4

Explanation: While the action addresses a critical compliance issue, a reverse stock split is generally viewed as a negative indicator reflecting a low share price and potential underlying business challenges. The company's continued losses and accumulated deficit also contribute to a cautious sentiment, despite the necessary step to maintain listing.

Positives

• The company is taking a concrete step to address its Nasdaq listing deficiency, which is crucial for continued trading on the exchange.
• The reverse stock split is expected to increase the market price of the common shares, potentially curing the Bid Price Rule deficiency.
• Stockholders previously approved the resolution for a reverse stock split, indicating alignment with the board's decision.

Negatives

• The necessity of a reverse stock split indicates a sustained low share price, which is generally a negative signal about the company's market valuation and investor confidence.
• Reverse stock splits can sometimes lead to decreased liquidity and further share price declines post-split.
• The company has an accumulated deficit and expects continued losses, as noted in its forward-looking statements.

Risks

• There is a risk that the reverse stock split may not effectively cure the Nasdaq Bid Price Rule deficiency or that the company may not maintain compliance in the future.
• Clinical results or early results may not be indicative of future results.
• The company's ability to fund its operations and continue as a going concern is a risk.
• The company has an accumulated deficit and expects continued losses.
• General risks discussed in the Risk Factors section of the company's most recently filed Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent filings.

Future Outlook

The company believes the reverse stock split will increase the market price for its Common Shares and cure the deficiency in the Nasdaq Bid Price Rule, allowing it to maintain its listing. It continues to develop next-generation therapies for neurodegenerative disorders, including Alzheimer's disease.

Management Comments

• ProMIS believes that the reverse stock split will increase the market price for its Common Shares and cure the deficiency in the Bid Price Rule.

Industry Context

This announcement is specific to ProMIS Neurosciences' compliance with Nasdaq listing requirements, rather than a broader industry trend. However, maintaining a Nasdaq listing is critical for biotechnology companies like ProMIS to access capital markets and maintain investor visibility, which is a common challenge for clinical-stage companies with long development timelines and no current revenue.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• Shareholders: Will own fewer shares, but each share will represent a proportionally larger ownership interest. Those with fractional shares will receive cash. The goal is to maintain Nasdaq listing, which benefits shareholders by preserving liquidity and market access.
• Employees: Proportional adjustments to equity incentive plans, stock options, and other equity securities.
• Nasdaq: The action is intended to bring the company into compliance with listing rules.

Next Steps

• Common Shares will begin trading on a split-adjusted basis on The Nasdaq Capital Market at market open on November 28, 2025.
• The company aims to regain and maintain compliance with Nasdaq's minimum bid price rule.
• Continued development of therapeutic antibodies and vaccines for neurodegenerative disorders.

Key Dates

Recommendation

The reverse stock split is a necessary defensive measure to maintain Nasdaq listing, addressing a critical compliance issue. While it removes an immediate delisting threat, it does not fundamentally change the company's underlying business prospects or financial health, which still include an accumulated deficit and expected continued losses. Investors should hold to observe if the company can sustain Nasdaq compliance and demonstrate progress in its clinical-stage biotechnology programs, as the reverse split itself is not a catalyst for significant positive revaluation without further operational improvements.

Keywords

ProMIS Neurosciences, PMN, Reverse Stock Split, Nasdaq Compliance, Biotechnology, Neurodegenerative Disorders, Alzheimer's Disease, Stock Market, Share Consolidation, SEC Filing